Moreover, in luminal A breast cancer patients, advanced disease was associated with a shift towards higher representation of intermediate (CD14+ CD16 +) over classical (CD14hi CD16−) monocytes [104], reflecting the lack of immunosuppression associated with this subtype [69]. Here, CD14 is linked to breast cancer.